GSKGLAXF 69 3-Year EBITDA Growth Rate is 6.30% as of Mar. 2026, which is 11% above its 10-year median of 5.70. GuruFocus rates GLAXF with a GF Score™ of 69/100 and a GF Value™ of $21.85 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 813 Drug Manufacturers companies, GSK ranks worse than 54.24% on this metric.
During the past 12 months, GSK's average EBITDA Per Share Growth Rate was 37.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 6.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 3.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 0.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of GSK was 96.10% per year. The lowest was -41.40% per year. And the median was 5.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
GSK 3-Year EBITDA Growth Rate Related Terms
GLAXF vs LLY, JNJ, ABBV: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - General subindustry, GSK's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GSK 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GSK's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where GSK's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 6.30% mean?
GSK (GLAXF) has a 3-Year EBITDA Growth Rate of 6.30% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for GSK and its competitors. This is 11% above median its historical median of 5.70. According to the industry distribution chart, GSK ranks #441 out of 813 companies in the Drug Manufacturers industry, placing it in the top 54.2%.
Is GSK's 3-Year EBITDA Growth Rate too high?
GSK's current 3-Year EBITDA Growth Rate of 6.30% is 11% above median its 10-year median of 5.70. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. GSK's value of 6.30% is 29.2% below this industry median. Based on the distribution chart, GSK ranks #441 out of 813 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, GSK has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's 3-Year EBITDA Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GSK ranks #441 out of 813 companies for 3-Year EBITDA Growth Rate. This places GSK in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. GSK's value of 6.30% is 29.2% below this benchmark. While the company's 10-year median is 5.70 vs. the industry median of 8.90, GSK has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GSK's current 3-Year EBITDA Growth Rate of 6.30% is 29.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for GSK and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GSK's current 3-Year EBITDA Growth Rate is 6.30%, which is 11% above median its own 10-year median of 5.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.85, compared to a current price of $26.29 — trading 20.3% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 6.30%, which is 11% above median its 10-year median of 5.70 and 29.2% below the Drug Manufacturers industry median of 8.90. GSK's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For GSK (GLAXF), the current 3-Year EBITDA Growth Rate is 6.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GSK (GLAXF) Overvalued in 2026?
Based on GuruFocus' analysis, GSK stock appears to be overvalued.
The current stock price of $26.29 is trading 20.3% above its estimated GF Value™ of $21.85.
GuruFocus considers GSK to be Modestly Overvalued.
Key valuation signals for GLAXF:
3-Year EBITDA Growth Rate: 6.30% (11% above median its 10-year median of 5.70)
GF Value™: $21.85 vs. price of $26.29 (20.3% above fair value)
Industry Position: 29.2% below the Drug Manufacturers median (#441 of 813)
No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
69GF Score
Get the complete analysis for GLAXF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLAXF has been successfully added to your 